



**THE FOUNDATION
FOR SECURE
MARKETS®**

#53962

Date: January 17, 2024

Subject: HUGE1 Options - Expiration Pricing Consideration

HUGE1 (adjusted FSD Pharma Inc. options) will be subject to special pricing consideration in expiration processing on January 19, 2024. The pricing consideration is due to the undetermined trading status of the Celly Nutrition Corporation shares included in the HUGE1 options deliverable. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

HUGE1

HUGE1 options are adjusted FSD Pharma Inc. options, adjusted November 30, 2023 (see OCC Information Memo #53637). The deliverable of HUGE1 options is:

DELIVERABLE

PER CONTRACT:

- 1) 100 FSD Pharma Inc. (HUGE) Class B Subordinate Voting Shares
- 2) 100 Celly Nutrition Corporation (subject to delayed settlement until the trading status can be determined)

As of January 17, 2024, the trading status for the Celly Nutrition Corporation shares has yet to be determined.

For purposes of calculating HUGE1 price for use in expiration processing, OCC will use the following formula:

$$\text{HUGE1} = \text{HUGE}$$

For example, if HUGE closes at 0.91, the HUGE1 price would be:

$$\text{HUGE1} = 0.91$$

This formula does not include an estimate of the value of the Celly Nutrition Corporation Shares.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.